Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
| Autor: | M Weisman, Marc Feldmann, J. R. Kalden, E W St Clair, F. C. Breedveld, Daniel E. Furst, Ravinder Nath Maini, Peter E. Lipsky, Paul Emery, Josef S. Smolen, Gregory Harriman, D. van der Heijde |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty business.industry Arthritis General Medicine medicine.disease Placebo Gastroenterology Infliximab Rheumatology Surgery Pharmacotherapy Internal medicine Rheumatoid arthritis Concomitant Therapy medicine Methotrexate skin and connective tissue diseases business medicine.drug |
| Zdroj: | New England Journal of Medicine. 343:1594-1602 |
| ISSN: | 1533-4406 0028-4793 |
| Popis: | Background: Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to effect a more sustained benefit and its effect on joint damage are not known. Methods: We treated 428 patients who had active rheumatoid arthritis despite methotrexate therapy with placebo or infliximab, a chimeric monoclonal antibody against TNF-α in intravenous doses of 3 or 10 mg per kilogram of body weight every 4 or 8 weeks in combination with oral methotrexate for 54 weeks. We assessed clinical responses with use of the criteria of the American College of Rheumatology, the quality of life with a health-status questionnaire, and the effect on joint damage radiographically. Results: The combination of infliximab and methotrexate was well tolerated and resulted in a sustained reduction in the symptoms and signs of rheumatoid arthritis that was significantly greater than the reduction associated with methotrexate therapy alone (clinical response, 51.8 percent vs. 17.0 percent; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|